TuesdayJul 18, 2017 2:39 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Well-positioned For Expanding Canadian Cannabinoid Market

Lexaria Bioscience Corp. well-positioned for growth in expanding Canadian cannabinoid market Canadian market for cannabis extracts and oils expected to top C$1.6 billion by 2020 Company’s patented technology infuses organically sourced hemp oil into molecules of other substances such as lipids, the basis of the human endocannabinoid system Patented technology enables better-tasting hemp oil-infused gourmet food products with improved bioavailability of cannabinoids Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth in the emerging Canadian cannabinoid market. Lexaria is an innovative revenue-generating company developing and out-licensing proprietary technology for delivering bioactive compounds including cannabinoids. With full legalization expected…

Continue Reading

WednesdayJul 12, 2017 12:48 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is “One to Watch”

Revenue-generating biosciences company focused on improving the delivery of bioactive compounds through gourmet foods Proprietary technology shown to enhance the bioavailability of orally ingested cannabinoids while improving the taste Actively developing and selling hemp oil-based gourmet food products through consumer brands ViPova™ and Lexaria Energy Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a…

Continue Reading

ThursdayJul 06, 2017 2:55 pm

Invictus MD (TSX.V: IMH) (OTC: IVITF) Poised to Have First-Mover Advantage in Canada’s Legal Cannabis Market

One of few Canadian cannabis companies to declare dividends Poised for first-mover advantage in Canada’s legal marijuana market 250 acres of cultivation space spanning from Alberta to Ontario Retail sales in Canada’s recreational marijuana market could climb to $6.0 billion by 2021, according to Deloitte Canadian, and Invictus MD Strategies Corp. (TSX.V: IMH) (OTC: IVITF) is strategically positioned to grow right alongside this burgeoning market and gain first-mover advantage as soon as Canada’s cannabis market is freed up by the necessary legislative regulations. Founded in Vancouver, Canada, Invictus MD is a cannabis company that is dedicated to offering high-quality, regulated…

Continue Reading

WednesdayJul 05, 2017 12:45 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Focused on the Science of Cannabinoids

Science-based cannabinoid pharmaceuticals are big market winners InMed Pharmaceuticals is developing two potential blockbuster drugs IMLFF has innovative and disruptive market advantages The market is rife with hype, pretenders and wannabes in the booming cannabis markets. In the rush to find the next hot cannabis stock, investors often overlook the real value in long-term scientific applications, and, after the heady hoopla of once-illicit marijuana dies down, those that chose science will be the ultimate winners. The medicinal and scientific applications of the 90 individual cannabinoid drugs found in cannabis are where the real value lies. Look no further than GW…

Continue Reading

WednesdayJul 05, 2017 8:54 am

Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) is a Technology Disruptor for Edible Cannabinoids

First mover in plant-to-bloodstream niche Proprietary technology improving bioavailability of orally ingested cannabinoids Two distinct consumer product brands: ViPova™ and Lexaria Energy With the recreational market set for legalization on July 1, 2018, Canada’s cannabis industry is experiencing a high that is catalyzing innovation in the biosciences sector. Pioneering biopharmaceutical companies there and in other developed countries are working to develop a variety of healthful products based on their research into cannabinoids. As a result, investment capital flow to “plant-to-bloodstream” companies is expected to swell just as it has been doing for “seed-to-plant” companies for some time, and innovative British…

Continue Reading

ThursdayJun 29, 2017 3:59 pm

Future Farm Technologies, Inc. (CSE: FFT) (OTCQB: FFRMF) Launches Its New and Expanded Interactive Website

LED lighting producer and leading indoor plant growth solutions provider Focused on efficiencies for the legal cannabis industry Website is now SEO-optimized, providing an easier way to order product Future Farm Technologies, Inc. (CSE: FFT) (OTCQB: FFRMF) has fully updated and SEO-optimized its e-commerce website (www.LEDCanada.com) in response to rising consumer demand for LED grow lights. The new and expanded site has gone live, and the LED product line can be viewed on LEDCanada.com. The site now contains a number of social media buttons for Facebook, Twitter, and Pinterest. The LEDCanada.com website will be updated with the newest content from…

Continue Reading

TuesdayJun 27, 2017 2:27 pm

Invictus MD (OTC: IVITF) (TSX.V: IMH): A Cannabis Company Living Up to its Name

Canadian Cannabis Valuations up 200% in two years 250 acres of cultivation space stretching from Alberta to Ontario Paid out $1,000,000 in Dividends representing $0.07 per Share It might just be that Invictus MD Strategies Corp. (OTC: IVITF) (TSX.V: IMH) (FRA: 8IS) has adopted as a motto the elevating penultimate line from William Ernest Henley’s immortal poem Invictus: “I am the master of my fate”. Canada’s Cannabis Company appears completely unafraid as it ploughs ahead with its strategy to become a dominant company in Canada’s cannabis space. That boldness is paying off; Invictus is one of only a handful of…

Continue Reading

MondayJun 26, 2017 2:52 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Targeting Blockbuster Therapeutics

The medical efficacy of cannabinoids to treat a multiplicity of maladies is no longer in doubt. Two recently published scientific studies dispelled any apprehensions about cannabis-based therapies. The highly respected New England Journal of Medicine published a peer reviewed article that proved in a controlled study that cannabidiol dramatically reduced the number of convulsive seizures in children stricken with a severe epileptic disorder (http://nnw.fm/i0X0D). The results of this study follow a comprehensive report by the National Academies of Science, Engineering, and Medicine which confirmed that cannabinoids are effective at treating chronic pain and for providing relief from nausea and vomiting…

Continue Reading

ThursdayJun 22, 2017 3:41 pm

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) Takes Additional Step toward Clinical Trials for INM-750

Moving toward offering the very first therapy for treating epidermolysis bullosa (EB), InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) recently announced it has signed an agreement with Pharmaseed Ltd. (http://nnw.fm/4lZzC) to develop a final formulation for INM-750, InMed’s lead compound, which is being developed as a therapy for EB and for other potential dermatological and wound-healing applications. EB is a group of inherited connective tissue diseases sharing a common manifestation of very fragile skin that is prone to easily blistering or tearing. An orphan disease that currently has no approved treatments and has significant unmet medical need, EB results from…

Continue Reading

MondayJun 05, 2017 8:00 am

ABcann Global (TSXV: ABCN) Target Price Set At $2.25 as Coverage is Initiated

Now that shares of ABcann Global Corporation (TSXV: ABCN) are trading on the venture arm of the Toronto Stock Exchange (TSX), the company is creating more buzz than ever. On the same day it launched its initial public offering (IPO) (May 4), industry analysts PI Financial initiated coverage of the stock with a decidedly bullish report (http://nnw.fm/zcgG2) on the company. PI has put a “Buy” rating on the stock and set a one-year price target of $2.25, implying a return of well over 100 percent. The investment bank backs up this sunny prognosis with an in-depth look at ABcann’s value…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000